PARK2 promotes mitochondrial pathway of apoptosis and antimicrotubule drugs chemosensitivity <i>via</i> degradation of phospho-BCL-2
Hengxing Chen, Yun Li, Yu Li, Zhen Chen, Li‐Min Xie, Wenjia Li, Yuanxin Zhu, Hong Xue, H. Phillip Koeffler, Wenjing Wu, Kaishun Hu, Dong Yin
Abstract
Our findings explained why PARK2 selectively confers chemosensitivity to antimicrotubule drugs, but not to DNA-damaging drugs. In addition, we identified PARK2 as a novel mediator of antimicrotubule drugs sensitivity, which can predict response of breast cancer patients to antimicrotubule drugs-containing regime.
Topics & Concepts
Cancer researchBreast cancerCisplatinChemotherapyIn vivoApoptosisBiologyCancerPaclitaxelMedicineInternal medicineBiotechnologyBiochemistryParkinson's Disease Mechanisms and TreatmentsPARP inhibition in cancer therapyCancer Treatment and Pharmacology